MedPage Today August 2, 2024
— Infliximab copycat usage varies widely with payer type
Infliximab biosimilars have taken an increasing share of prescriptions for the first tumor necrosis factor (TNF) inhibitor to win approval, but some payers have been more willing than others to cover these products — with the U.S. government so far being the least willing.
From 2016 to 2022, private insurance, Medicaid, and Medicare all substantially increased the proportion of infliximab prescriptions for which biosimilar versions were provided. But the increase was much slower under Medicare compared with the other two payer types, according to Eric T. Roberts, PhD, of the University of California San Francisco, and colleagues writing in Arthritis & Rheumatology.
Specifically, mean annual rate increases during 2016-2020 — the...
Today's Sponsors
Today's Sponsor